Management tracks: Cellectis, Navitor

Zafgen Inc. (NASDAQ:ZFGN) CEO Thomas Hughes has stepped down from the metabolic disease company to become CEO at Navitor Pharmaceuticals Inc. (Cambridge, Mass.). Zafgen is seeking a successor. In June, Navitor begin Phase I testing of lead candidate NV-5138, a mammalian target of rapamycin complex 1 (mTORC1) activator, for treatment-resistant depression.

Immunotherapy company Cellectis S.A. (Euronext:ALCLS; NASDAQ:CLLS) hired Stefan Scherer as SVP of clinical development and deputy CMO. He was head of early development, strategy and innovation for U.S. oncology at Novartis AG (NYSE:NVS; SIX:NOVN), where he headed the company's immuno-oncology and targeted therapy portfolios...